Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

Blood (2024) 143 (23): 2363–2372.

https://doi.org/10.1182/blood.2023023502

Published: 2024

Includes: Supplemental data

Journal Articles

Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study

Sylvain Garciaz, Sarah Bertoli, David A Sallman, Justine Decroocq, Pierre-Yves Dumas, Amine Belhabri, Corentin Orvain, Gaspar Aspas Requena, Celestine Simand, Kamel Laribi, Martin Carré, Alberto Santagostino, Ludovic Gabellier, Marie Anne Hospital, Ariane Mineur, Arnaud Pigneux, Norbert Vey, Christian Récher

Blood (2023) 142 (Supplement 1): 161.

https://doi.org/10.1182/blood-2023-185437

Published: 2023

Journal Articles

Exploring the Heterogeneity of Response to Blinatumomab in High-Risk Philadelphia-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: An Analysis from the QUEST Sub-Study of the Graall-2014/B Trial

Blood (2023) 142 (Supplement 1): 4349.

https://doi.org/10.1182/blood-2023-177847

Published: 2023

Journal Articles

Long-Term Outcome of Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation (ASCT) - Impact of Therapeutic Strategy Following ASCT

Emilie Martin, Stéphane Morisset, Mohamad Sobh, Alfred Quillon, Hélène Boyer, Philippe Rey, Emmanuelle Nicolas-Virelizier, Amine Belhabri, Yann Guillermin, Laure Lebras, Valérie Mialou, Jean Paul Bourgeot, Melinda Teyssier, Anne-Sophie Michallet, Mauricette Michallet

Blood (2023) 142 (Supplement 1): 6682.

https://doi.org/10.1182/blood-2023-182700

Published: 2023

Journal Articles

CPX-351 in Patients with Newly Diagnosed Post Myeloproliferative Neoplasms Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2917.

https://doi.org/10.1182/blood-2023-184591

Published: 2023

Journal Articles

Fms-like Tyrosine Kinase 3 Ligand Kinetic Profile Is the Strongest Factor Predicting Refractoriness after Induction and Event-Free Survival in Adults with AML: A Filo Prospective Multicentric Study

Blood (2023) 142 (Supplement 1): 975.

https://doi.org/10.1182/blood-2023-173518

Published: 2023

Journal Articles

Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory Settings: A Multicentric Study from French Auraml Group

Zofia Gross, Urbain Tauveron-Jalenques, Gaspar Aspas Requena, Martin Carre, Mathieu Meunier, Emmanuelle Tavernier, Jérôme Cornillon, Amine Belhabri, Mauricette Michallet, Adrien Contejean, Natacha Mauz, Boullanger FOW HENG Nadine, Daciana Claudia Antal, Gian Matteo Pica, Dony Arthur, Clémence Santana, Clement Rocher, Mael Heiblig

Blood (2023) 142 (Supplement 1): 590.

https://doi.org/10.1182/blood-2023-187331

Published: 2023

Journal Articles

Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience

Blood (2022) 140 (Supplement 1): 12335–12338.

https://doi.org/10.1182/blood-2022-163478

Published: 2022

Journal Articles

Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study

Blood (2022) 140 (Supplement 1): 507–509.

https://doi.org/10.1182/blood-2022-159397

Published: 2022

Journal Articles

Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO)

Sylvain Garciaz, Justine Decroocq, Sarah Bertoli, Amine Belhabri, Pierre-Yves Dumas, Celestine Simand, Kamel Laribi, Alberto Santagostino, Martin Carre, Aline Schmidt, Gaspard Aspas Requena, Chantal Himberlin, Marie-Anne Hospital, Christian Recher, Norbert Vey

Blood (2022) 140 (Supplement 1): 6147–6148.

https://doi.org/10.1182/blood-2022-158247

Published: 2022

Journal Articles

Venetoclax Pharmacokinetics in Real World AML Patients: A Real Candidate for Therapeutic Drug Monitoring

Michael Philippe, Jerome Guitton, Bertrand Favier, Clemence Santana, Emmanuelle Nicolas-Virelizier, Yann Guillermin, Anne-Sophie Michallet, Mauricette Michallet, Amine Belhabri

Blood (2022) 140 (Supplement 1): 6179–6180.

https://doi.org/10.1182/blood-2022-168327

Published: 2022

Journal Articles

Therapy-Related Acute Myeloid Leukemia (t-AML) and the Advantage of Intensive Chemotherapy: Real-Life Analysis from Two Regional French Centers

Blood (2021) 138 (Supplement 1): 4379.

https://doi.org/10.1182/blood-2021-148678

Published: 2021

Journal Articles

The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study

Blood (2021) 138 (Supplement 1): 512.

https://doi.org/10.1182/blood-2021-148843

Published: 2021

Journal Articles

Comparison of a Combination of Vosaroxin (VOS) and Intermediate-Dose Cytarabine (IDAC) with Idac for the Consolidation Therapy of Younger Patients with Favorable- and Intermediate-Risk Acute Myeloid Leukemia (AML) in First Complete Remission (CR): Preliminary Results of a Randomized Phase 2 R4-VOS Study of the French ALFA-Filo AML Intergroup

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-137032

Published: 2020

Journal Articles

Study of Treatment Complications in Oncology / Hematology Patients: Protocol for a Prospective and Interventional Cohort Study from the Pasca Program

Mauricette Michallet, MD PhD, Romain Buono, PharmD, Mohamad Sobh, PharmD, Solene Poirey, Emmanuelle Nicolas-Virelizier, MD, Souad Assaad, MD, Amine Belhabri, MD, Laure Lebras, MD, Yann Guillermin, MD, Philippe Rey, MD, Aude Flechon, MD PhD, Helen Boyle, MD, Franck E Nicolini, MDPhD, Audrey Couillet, Gisele Chvetzoff, Jean-Yves Blay, MD PhD, Beatrice Fervers, Anne-Sophie Michallet, MD PhD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-142355

Published: 2020

Journal Articles

Characteristics and Outcomes of Therapy-Related Acute Myeloid Leukemia: Results of Retrospective Analysis of 116 Adult Patients

Amine Belhabri, MD, Liliana Vila, MD, Mael Heiblig, Stephane Morisset, BioStat, Emmanuelle Nicolas-Virelizier, MD, Clémence Santana, MD, Isabelle Tigaud, MD, Sandrine Hayette, PhD, Anne-Sophie Michallet, MD PhD, Philippe Rey, MD, Yann Guillermin, MD, Souad Assad, MD, Laure Lebras, MD, Mauricette Michallet, MD PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-142956

Published: 2020

Journal Articles

Therapy Related Myeloid Neoplasm Post PARP Inhibitors: Potential Clonal Selection.

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-139971

Published: 2020

Journal Articles

Personalised Follow-up Program after Acute Phase of Treatment in Oncology/Hematology Patients Towards Early Intervention, Better Care and Quality of Life Improvement: Results from Pasca Pilot Study

Mauricette Michallet, MD PhD, Mohamad Sobh, PharmD, Romain Buono, Solene Poirey, Isabela Pascu, Emmanuelle Nicolas-Virelizier, MD, Souad Assaad, MD, Amine Belhabri, Laure Lebras, MD, Yann Guillermin, MD, Philippe Rey, MD, Lila Gilis, MD, Franck E Nicolini, MD PhD, Stephane Morisset, BioStat, Audrey Couillet, Gisele Chvetzoff, Jean-Yves Blay, MD PhD, Beatrice Fervers, Anne-Sophie Michallet, MD PhD

Blood (2019) 134 (Supplement_1): 5817.

https://doi.org/10.1182/blood-2019-130597

Published: 2019

Journal Articles

A Lysa Phase II Study of Oral JAK1/2 Inhibitor Ruxolitinib in Advanced Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)

Eric W Van Den Neste, MD PhD, Marc Andre, MD, Thomas Gastinne, MD, Aspasia Stamatoullas, MD, Corinne Haioun, MD PhD, Amine Belhabri, MD, Oumedaly Reman, MD, Olivier Casasnovas, MD, Herve Ghesquieres, MD PhD, Gregor Verhoef, MD PhD, Marie-José Claessen, Hélène A Poirel, Marie-Christine Copin, Romain Dubois, Peter Vandenberghe, MD PhD, Ioanna-Andrea Stoian, Anne Ségolène Cottereau, MD, Laurent Knoops, MD PhD, Franck Morschhauser

Blood (2016) 128 (22): 4160.

https://doi.org/10.1182/blood.V128.22.4160.4160

Published: 2016

Journal Articles

Impact of the Use of Polymerase Chain Reaction for the Diagnosis and Management of Pneumocystis Jirovecii Pneumoniae in a Retrospective Cohort of Patients with Lymphoid Malignancies

Felicite De Charry, MD, Damien Dupont, PharmD, Meja Rabodonirina, MD PhD, Celine Ferlay, Ms, Christine Fuhrmann, MD, Emmanuelle Nicolas-Virelizier, MD, Philippe Rey, MD, Catherine Sebban, MD, Amine Belhabri, MD, Pierre Biron, MD, Jean-Yves Blay, Herve Ghesquieres, MD PhD

Blood (2016) 128 (22): 688.

https://doi.org/10.1182/blood.V128.22.688.688

Published: 2016

NARROW

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study

Exploring the Heterogeneity of Response to Blinatumomab in High-Risk Philadelphia-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: An Analysis from the QUEST Sub-Study of the Graall-2014/B Trial

Long-Term Outcome of Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation (ASCT) - Impact of Therapeutic Strategy Following ASCT

CPX-351 in Patients with Newly Diagnosed Post Myeloproliferative Neoplasms Acute Myeloid Leukemia

Fms-like Tyrosine Kinase 3 Ligand Kinetic Profile Is the Strongest Factor Predicting Refractoriness after Induction and Event-Free Survival in Adults with AML: A Filo Prospective Multicentric Study

Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory Settings: A Multicentric Study from French Auraml Group

Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience

Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study

Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO)

Venetoclax Pharmacokinetics in Real World AML Patients: A Real Candidate for Therapeutic Drug Monitoring

Therapy-Related Acute Myeloid Leukemia (t-AML) and the Advantage of Intensive Chemotherapy: Real-Life Analysis from Two Regional French Centers

The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study

Study of Treatment Complications in Oncology / Hematology Patients: Protocol for a Prospective and Interventional Cohort Study from the Pasca Program

Characteristics and Outcomes of Therapy-Related Acute Myeloid Leukemia: Results of Retrospective Analysis of 116 Adult Patients

Therapy Related Myeloid Neoplasm Post PARP Inhibitors: Potential Clonal Selection.

Personalised Follow-up Program after Acute Phase of Treatment in Oncology/Hematology Patients Towards Early Intervention, Better Care and Quality of Life Improvement: Results from Pasca Pilot Study

A Lysa Phase II Study of Oral JAK1/2 Inhibitor Ruxolitinib in Advanced Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)

Impact of the Use of Polymerase Chain Reaction for the Diagnosis and Management of Pneumocystis Jirovecii Pneumoniae in a Retrospective Cohort of Patients with Lymphoid Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only